natural killer ( nk ) cell activity against k 562 erythroleukemic- and mcf-7 breast carcinoma-derived cells was monitored in short-term ( 3 h/k 562 ) and long-term ( 18 h/mcf-7 ) chromium release tests for 60 patients with untreated primary breast disease .
C0006142
breast carcinoma
C0006141
breast